- Home
- Services
- australasia
- gene therapy vector
Refine by
Gene Therapy Vector Services Available In Australasia
7 services found
by:Revvity Gene Delivery (formerly SIRION Biotech) based inHamburg, GERMANY
At Revvity, we work with you to expedite the development of gene therapy vectors. ...
by:Expression Systems, LLC based inDavis, CALIFORNIA (USA)
Leveraging its experience, expertise, and passion for the BEVS platform, Expression Systems provides a comprehensive array of services for manufacturing recombinant proteins, vaccines and gene therapy vectors. We specialize in the BEVS platform and take pride in our history of successfully completing projects where other more generalized CMOs ...
by:Andelyn Biosciences based inColumbus, OHIO (USA)
Andelyn offers innovative services that are designed to accelerate biopharmaceutical and cell & gene therapy projects through AAV vector development. We have 16+ customizable production suites ranging from 50L to 2000L suspension-based manufacturing platforms, as well as sixty 36-layer HYPERStacks per sublot. With solutions that cover the ...
by:Expression Systems, LLC based inDavis, CALIFORNIA (USA)
Expression Systems’ contract production services can assist you at any step of the process, solving technical problems in molecular biology, purification or other issues relating to BEVS. ...
Manufactured by:Matica Biotechnology, Inc. based inCollege Station, TEXAS (USA)
At Matica Biotechnology’s 25,000-square-foot GMP facility in College Station, Texas, we offer fully integrated solutions for cell and gene therapies, vaccines, oncolytic vectors and other biotherapeutic ...
by:Andelyn Biosciences based inColumbus, OHIO (USA)
At Andelyn Biosciences, we’re an ideal viral vector CDMO partner. We work closely with you throughout the entire process of developing your cell and gene therapy or vaccine – from the initial process of development and research to creating a reliable and consistent clinical and commercial supply. ...
Manufactured by:ProBioGen AG based inBerlin, GERMANY
You want to overcome the historic way to manufacture viral vaccines on embryonated chicken eggs or on finite cultures of primary avian and mammalian origin. You want to avoid challenges in supply and scalability, variable performance, and increasing costs for source material and extensive safety testing. You are looking for a modern serum-free process avoiding traditional, technically demanding ...